Related Experiment Video
Updated: May 21, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Hypoglycemia in type 2 diabetes: current controversies and changing practices
Zachary T Bloomgarden1, Daniel Einhorn
1Mount Sinai School of Medicine New York, NY, USA.
Frontiers in Endocrinology
|June 5, 2012
Summary
Hypoglycemia, or low blood sugar, complicates diabetes management. Understanding why some patients experience more hypoglycemia, even with higher A1c, is key to improving treatment safety and outcomes.
Area of Science:
- Endocrinology and Metabolism
- Diabetes Mellitus Research
- Clinical Glycemic Control
Background:
- Hypoglycemia (low blood sugar) is a significant barrier to achieving optimal glycemic control in individuals with diabetes.
- The relationship between A1c levels and hypoglycemia risk differs between type 1 and type 2 diabetes, presenting a paradox in treatment.
- Previous studies, such as the ACCORD trial, have indicated adverse outcomes potentially linked to hypoglycemia in certain diabetic populations.
Purpose of the Study:
- To explore the complex relationship between glycemic control (A1c levels) and the incidence of hypoglycemia in different diabetes types.
- To investigate the paradoxical observation of increased hypoglycemia in insulin-treated type 2 diabetes patients with higher A1c.
- To identify factors contributing to hypoglycemia risk to improve therapeutic strategies and patient outcomes in diabetes management.
Main Methods:
- Analysis of existing literature and clinical data concerning hypoglycemia in type 1 and type 2 diabetes.
- Review of factors influencing glycemic control and the occurrence of hypoglycemic events.
- Examination of patient characteristics associated with an increased likelihood of experiencing hypoglycemia.
Main Results:
- In type 1 diabetes, lower A1c levels correlate with a higher risk of hypoglycemia.
- Insulin-treated type 2 diabetes patients with higher A1c levels paradoxically exhibit a greater frequency of hypoglycemia.
- This increased hypoglycemia in type 2 diabetes may contribute to adverse outcomes observed in major clinical trials like ACCORD.
Conclusions:
- Developing glucose-lowering strategies with a reduced risk of hypoglycemia is crucial for effective diabetes management.
- Advancements in technology for detecting hypoglycemic events are needed to better monitor and manage patient safety.
- A deeper understanding of patient-specific factors is essential to mitigate the risk of hypoglycemia and optimize glycemic treatment.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...